Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Cancer metastasis to the upper gastrointestinal tract-a case series.
J Gastrointest Oncol
December 2024
Medical Oncology Department, The Canberra Hospital, Canberra, ACT, Australia.
Background: Metastasis of non-gastrointestinal (non-GI) cancers to the upper GI tract is a rare occurrence, with limited cases reported in the literature. Recognising this type of metastasis is crucial, as it presents unique diagnostic and therapeutic challenges. This case series adds to the literature by discussing seven rare cases of non-GI cancer metastasising to the upper GI tract, emphasising the complications and clinical manifestations.
View Article and Find Full Text PDFSilent Shadows: Unveiling the Psoas Abscess and Its Treatment.
Cureus
October 2024
General Surgery, Crystal Run Healthcare, Middletown, USA.
Iliopsoas abscesses are a rare complication of appendicitis and are associated with high morbidity and mortality without appropriate intervention. Current literature provides sufficient evidence for managing psoas abscesses via antimicrobial therapy, CT-guided percutaneous drainage, and laparoscopic or open drainage as primary approaches. However, there is insufficient data in the current literature for assessing improved patient outcomes with robotically assisted laparoscopic drainage as an approach to treatment.
View Article and Find Full Text PDFSmall Bowel Perforation Due to Renal Carcinoma Metastasis: A Comprehensive Case Study and Literature Review.
Diagnostics (Basel)
April 2024
Department of Pathology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
This case report presents a unique instance of small bowel perforation caused by solitary metastasis from renal cell carcinoma (RCC), a rare and complex clinical scenario. The patient, a 59-year-old male with a history of RCC treated with nephrectomy four years prior, presented with acute abdomen symptoms. Emergency diagnostic procedures identified a significant lesion in the small intestine.
View Article and Find Full Text PDFEfficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.
Oncologist
July 2024
Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Background: Tivozanib has been approved as a third-line or later therapy for advanced renal cell carcinoma based on the TIVO-3 trial, which was conducted before immune checkpoint therapies (ICT), cabozantinib, and lenvatinib/everolimus became incorporated in the current sequential treatment paradigm for advanced clear cell RCC (ccRCC).
Methods: We performed a retrospective study of patients with advanced ccRCC treated with tivozanib at MD Anderson Cancer Center during 6/2021-7/2023. A blinded radiologist assessed tumor response by RECIST v1.
Retrospective Analysis of Definitive Chemoradiotherapy With FOLFOX in Patients With Esophageal Cancer Intolerant to Cisplatin.
In Vivo
March 2024
Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan;
Background/aim: Definitive chemoradiotherapy with cisplatin (CDDP) plus 5-fluorouracil is the standard treatment for locally advanced esophageal squamous cell carcinoma (LA-ESCC); however, CDDP is unsuitable for patients with cardiac and/or renal dysfunction. Based on the results of the PRODIGE5/ACCORD17 trial, 5-fluorouracil and leucovorin with oxaliplatin plus radiotherapy (FOLFOX-RT) has been recognized as a treatment option. However, the efficacy and safety of FOLFOX-RT is still unclear in Japan.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!